Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 3Whole-Brain Radiotherapy 1Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Squamous Non-small Cell Lung Cancer 1Small Cell Lung Carcinoma 1Sarcoma, Synovial 1Sarcoma, Alveolar Soft Part 1Sarcoma 1Ovarian Neoplasms 1Nasopharyngeal Carcinoma 1Lung Neoplasms 1Leiomyosarcoma 1Fallopian Tube Neoplasms 1Extensive Small Cell Lung Cancer 1Endometrial Neoplasms 1Carcinoma, Hepatocellular 1Advanced Renal Cancer 1Advanced Non-small Cell Lung Cancer 1

Interventions

anlotinib 1Sunitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Advanced Renal Cancer × anlotinib × Clear all
NCT04523272 2024-10-15

A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Sunitinib in Subjects With Advanced Renal Cancer

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 3 Active not recruiting
528 enrolled

Advanced Renal Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡